EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSFHEG00000004369
Gene Symbol: GABRG2
3 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSFHEG00000019318
Gene Symbol: GABRG3
4 Cross references
219 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSFHEG00000000243
Gene Symbol: GABRG3
4 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSFHEG00000021663
Gene Symbol: GABBR1
4 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSFHEG00000023429
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSFHEG00000019228
Gene Symbol: GLP2R
4 Cross references
204 Possible Orthologues:

Glucagon Receptor-Like

Ensembl ID : ENSFHEG00000001819
Gene Symbol: LOC105926638
2 Cross references
203 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSFHEG00000011406
Gene Symbol: LOC105920641
3 Cross references
207 Possible Orthologues:

Glucokinase

Ensembl ID : ENSFHEG00000006791
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSFHEG00000021460
Gene Symbol: GBA1
3 Cross references
253 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSFHEG00000007386
Gene Symbol: GRIA2
2 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSFHEG00000009217
Gene Symbol: GRIN1
4 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).